Pralsetinib

Royalty Pharma Acquires Royalty Interest in Gavreto From Blueprint Medicines for up to $340 Million

Retrieved on: 
Thursday, June 30, 2022
RET, PTC, Patient, Communication, BPMC, Research, GLOBE, Marketing, Sale, MTC, U.S. Securities and Exchange Commission, AbbVie, Forward-looking statement, Terminology, NSCLC, Royalty Pharma, Thyroid, Publication, Partnership, Nasdaq, Roche, Transfection, Private Securities Litigation Reform Act, EDGAR, Blueprint, Papillary thyroid cancer, Medical imaging, Fine chemical, Elexacaftor/tezacaftor/ivacaftor, Pralsetinib

NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired an ex-U.S. royalty interest in Gavreto (pralsetinib) from Blueprint Medicines (Nasdaq: BPMC) for up to $340 million, consisting of $175 million upfront and up to $165 million in potential sales-based milestones.

Key Points: 
  • NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired an ex-U.S. royalty interest in Gavreto (pralsetinib) from Blueprint Medicines (Nasdaq: BPMC) for up to $340 million, consisting of $175 million upfront and up to $165 million in potential sales-based milestones.
  • "We are thrilled to establish this partnership with Royalty Pharma, a leader in funding innovation, said Kate Haviland, Chief Executive Officer of Blueprint Medicines.
  • Royalty Pharma is known to invest in transformative medicines, and their investment in Gavreto reinforces our confidence in its future.
  • Royalty Pharma is purchasing the ex-U.S. royalty payable by Roche through its full term, which is estimated to be through 2036 to 2040.

Insights from the world's leading KOLs on the prospects of launched and pipeline therapies for non-small cell lung cancer

Retrieved on: 
Thursday, October 14, 2021
Large-cell lung carcinoma, Amgen, Pharma, Industry, Eli Lilly and Company, Turning Point, Entrectinib, Lists of people executed in the United States, Classification, Daiichi Sankyo, Novartis, Roche, Sanofi, Merck Group, Intelligence, ADC, Brigatinib, NSCLC, Pralsetinib, Medtech, Blueprint, Osimertinib, Chemoradiotherapy, KOL, Research, Turning Point Alcohol and Drug Centre, Alectinib, Mirati, AstraZeneca, Pharmaceutical industry, Fine chemical

A comprehensive, qualitative review of targeted and novel therapies in the non-small cell lung cancer.

Key Points: 
  • A comprehensive, qualitative review of targeted and novel therapies in the non-small cell lung cancer.
  • In-depth interviews were conducted with 12 of the world's foremost KOLs in the United States and Europe.
  • How do KOLs assess Turning Point's pipeline repotrectinib and AnHeart's taletrectinib in the treatment of ROS1-positive NSCLC?
  • Why do KOLs expect Eli Lilly's late-stage Retevmo/Retsevmo and Blueprint Medicines/Roche's Gavreto will become front-line treatments for RET-fusion positive NSCLC?

Life-changing Medicines Arcalyst and Gavreto Now Available at AllianceRx Walgreens Prime

Retrieved on: 
Tuesday, September 28, 2021
Transfection, Cancer, Pharmacist, Patient, Recurrence, CAPS, FDA, Pharmacy, DIRA, Heart, Gene, Large-cell lung carcinoma, Solipsism syndrome, Risk, Muckle–Wells syndrome, Maintenance, Pralsetinib, Pericarditis, Cold urticaria, Deficiency, Fever of unknown origin, Pharmaceutical industry

"We are delighted these manufacturers chose AllianceRx Walgreens Prime to dispense these medications.

Key Points: 
  • "We are delighted these manufacturers chose AllianceRx Walgreens Prime to dispense these medications.
  • For full prescribing information and warnings for any of these medicines, visit the manufacturer websites or dailymed.nlm.nih.gov .
  • AllianceRx Walgreens Prime ( alliancerxwp.com ) is a specialty and home delivery pharmacy that strives to provide exceptional care throughout a patient's treatment journey with the medications they need every day.
  • The company is headquartered in Orlando, Fla. and its pharmacies are accredited by several national pharmacy accreditation services.

Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer

Retrieved on: 
Tuesday, December 1, 2020
Drugs, Health sciences, Breakthrough therapy, Orphan drugs, Life sciences, Lung cancer, Tyrosine kinase receptors, Genentech, South San Francisco, California, Pralsetinib, Hoffmann-La Roche, RET proto-oncogene

GAVRETO is jointly commercialized in the U.S. by Blueprint Medicines and Genentech, a wholly owned member of the Roche Group, under Blueprint Medicines' collaboration with Roche.

Key Points: 
  • GAVRETO is jointly commercialized in the U.S. by Blueprint Medicines and Genentech, a wholly owned member of the Roche Group, under Blueprint Medicines' collaboration with Roche.
  • Earlier this year, the FDA granted accelerated approval to GAVRETO for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.
  • The continued approval of GAVRETO for advanced or metastatic RET-altered thyroid cancers may be contingent upon verification and description of clinical benefit in confirmatory trials.
  • Blueprint Medicines is dedicated to helping patients access GAVRETO and delivering support throughout their treatment journey.

Genentech Announces FDA Approval of Gavreto (pralsetinib) for People With Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancers

Retrieved on: 
Tuesday, December 1, 2020
Oncology, FDA, Health, Clinical trials, Pharmaceutical, Biotechnology, Breakthrough therapy, Orphan drugs, Drugs, Lung cancer, Tyrosine kinase receptors, Organ systems, Health sciences, Papillary thyroid cancer, RET proto-oncogene, Thyroid cancer, Non-small-cell lung carcinoma, Pralsetinib, the ARROW study, RET-altered cancers, Gavreto, Genentech

Approximately 10-20% of people with papillary thyroid cancer (the most common type of thyroid cancer) have RET fusion-positive tumors, and roughly 90% of people with advanced MTC (a rare form of thyroid cancer) carry RET mutations.

Key Points: 
  • Approximately 10-20% of people with papillary thyroid cancer (the most common type of thyroid cancer) have RET fusion-positive tumors, and roughly 90% of people with advanced MTC (a rare form of thyroid cancer) carry RET mutations.
  • Biomarker testing for RET fusions and mutations can help identify people who are eligible for treatment with Gavreto.
  • In September, the FDA also granted accelerated approval to Gavreto for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.